After MDMA Legalization: The Path to Legal Psychedelics

With MAPS moving its historic Phase 3 MDMA trial towards FDA approval, the movement toward psychedelic legalization is gaining increasing momentum. The forthcoming FDA approval of MDMA will be a milestone that will likely accelerate the path toward legal psychedelics.

So what will happen next? The continuation of the ongoing multi-faceted approach. We take a closer look.

Psychedelic Research and Clinial Trials

Ongoing studies and clinical trials are adding to the evidence of effectiveness in different patient populations and exploring psychedelics’ potential benefits for other mental health conditions. Continued research will provide additional evidence for the safety and efficacy of psychedelic-assisted therapy, strengthening the case for broader legalization and FDA approval of other psychedelics.

Recent studies have continued to add to the growing amount of evidence, including Ketamine Improves Plasticity and Depression Results, New Study Shows SSRIs Ineffective Compared to Psychedelics, and Study Shows Psilocybin Reduces Drinking in 83% of Patients.

Late-stage clinical trials like Compass Pathways’ Phase 3 trial for depression and MindMed’s Phase 2b trial for anxiety will likely be the next trials to flirt with FDA approval of psychedelics.

Legislative Support for Psychedelic Legalization

Besides the FDA approval route, there are also legislative changes that could legalize psychedelics. Oregon became the first U.S. state to approve regulated psilocybin treatments, with efforts underway in other states as well. These legislative initiatives aim to establish frameworks for medical access and could potentially pave the way for broader decriminalization and legalization efforts.

Other recent news on this front include Kentucky Commits $42 Million for Psychedelic Research and Republican Lawmakers Introduce New Bill for Psychedelic Therapy

For more on this, check out Where Are Psychedelics Legal (or Decriminalized)?

Expanded Access Programs

Special Access Programs (SAP)  provide a means for individuals who do not qualify for clinical trials but could benefit from psychedelic therapies to access them under medical supervision. Expanded access programs create opportunities for a broader population to experience the therapeutic benefits of psychedelics while awaiting full legalization.

Countries like Canada are slowly starting to increase access for patients under SAPs, although progress under these frameworks is moving much slower than advocates would like.

See how non-profits like TheraPsil are suing governments to increase access for patients.

Advocacy and Public Education

Advocacy and public education will remain crucial for the future paths of psychedelic legalization. Educating the public, policymakers, and healthcare professionals about the potential therapeutic applications of psychedelics helps to dispel myths and stigmas surrounding these substances. Grassroots efforts, public campaigns, and collaboration between advocacy groups and researchers will play a vital role in shaping public opinion and influencing legislative changes.

Acceptance of psychedelic by mainstream audiences and celebrities also greatly help in influencing public opinion.

For more on this, check out Celebrity Update: CNN & Oprah Talk Psychedelic Healing and Psychedelic Medicine PAC (Political Action Committee) Launches in Washington

The post After MDMA Legalization: The Path to Legal Psychedelics appeared first on Microdose.

Read More